Register Now for NAAF's 39th Annual Patient Conference June 27-30, 2024 in Washington, D.C.!

A Study to Evaluate the Safety of an Investigational Topical JAK Inhibitor Suspension in Adults with Alopecia Areata

Study type: Clinical Trials Posting date: 05/22/2023 Last updated: 05/20/2024 Status: Recruiting Phase: Phase 1 Country: United States Eligibility:

18 to 70 years of age; patchy AA with 30% to 80% scalp hair loss

Drug: Investigational topical JAK inhibitor suspension Administration: Topical Sponsor: Arcutis Biotherapeutics Sponsor Link: Click here Location: Multiple locations


This study is evaluating the safety and tolerability of a topical form of an investigational JAK inhibitor in people with alopecia areata.

You may qualify to participate in this study if you:*

  • Are 18 to 70 years of age
  • Have patchy alopecia areata with 30-80% scalp hair loss

*There are additional requirements as determined by a screening process.

If you qualify, you will need to come to the study center up to 7 times over a 4 month period. At these visits, the study doctor will closely monitor your alopecia areata and discuss your overall experiences with the topical study drug and your participation in the study. Participation in this study is at no cost to you and you will be compensated for your time and travel.

If you would like to learn more about this study, please visit to evaluate if you may be eligible and then be directed to a research site located close to you. This study is taking place at locations throughout the United States:

  • Austin, Texas
  • San Antonio, Texas
  • Pittsburgh, Pennsylvania
  • Bexley, Ohio
  • Plainfield, Indiana
  • Minneapolis, Minnesota